<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
      <Volume-Issue>Volume 14,Issue 1 ,2022 </Volume-Issue>
      <Season>January-March 2022 </Season>
      <ArticleTitle>In vitro and ex vivo evaluation of triamcinolone acetonide-loaded transferosome gel-based novel carrier for the treatment of osteoarthritis</ArticleTitle>
          <FirstName>Ghanshyam Das</FirstName>
      <Abstract>Aim: Osteoarthritis is one of the prevalent disorders of the bone and is the leading cause of death across the globe. The poor survival rate and limited opportunities for treatment require the use of novel therapies to tackle the disease.&#13;
Objectives: In the present invention, we reported significant in vitro and ex vivo improvement of BCS Class IV drug, triamcinolone acetonide (TMA) in transferosome-based gel.&#13;
Materials and Methods: The optimized transferosome-based suspension (TMA-TS) reported nano-size range with negative zeta potential. Conversion of suspension to gel was initiated using Carbopol 934P as gel base. The spreadability, viscosity, and entrapment efficiency were found to be more enhanced in TMA-TG formulation, as compared to pure drug.&#13;
Results and Discussion: The spherical morphology of TMA-TS was confirmed in transmission electron microscopy. In vitro dissolution of TMA-TS augments multi-fold release behavior in TMA in phosphate buffer saline 7.4 as dissolution media. Remarkable permeability was observed in goat skin, as confirmed from ex vivo permeability experiments, as compared to suspension and pure drug. Stability studies indicated robustness of formulation during 3-month storage period.&#13;
Conclusion: In a nutshell, this microparticulate system is well suited and significantly enhanced the biopharmaceutical attributes of TMA.</Abstract>
      <Keywords>In vitro dissolution, Osteoarthritis, Permeability, Triamcinolone acetonide</Keywords>
        <Abstract>https://isfcppharmaspire.com/ubijournal-v1copy/journals/abstract.php?article_id=14098&amp;title=In vitro and ex vivo evaluation of triamcinolone acetonide-loaded transferosome gel-based novel carrier for the treatment of osteoarthritis</Abstract>
        <References>1. Rabiei M, Kashanian S, Samavati SS, Derakhshankhah H, Jamasb S, McInnes SJ. Nanotechnology application in drug delivery to osteoarthritis (OA), rheumatoid arthritis (RA), and osteoporosis (OSP). J Drug Deliv Sci Technol 2021;61:102011&#13;
2. Ghouri A, Conaghan PG. Prospects for therapies in osteoarthritis. Calcif Tissue Int 2021;109:339-50.&#13;
3. Bnyan R, Khan I, Ehtezazi T, Saleem I, Gordon S, O’Neil Fl, et al. Formulation and optimisation of novel transfersomes for sustained release of local anaesthetic. J Pharm Pharmacol 2019;71:1508-19.&#13;
4. El Afify MS, El Dein EA, Elsadek BE, Mohamed MA, El-Gizawy SA. Development and optimization of a novel drug free nanolipid vesicular system for treatment of osteoarthritis. Drug Dev Ind Pharm 2018;44:767-77.&#13;
5. Periyasamy PC, Leijten JC, Dijkstra PJ, Karperien M, Post JN. Nanomaterials for the local and targeted delivery of osteoarthritis drugs. J Nanomater 2012;2012:673968.&#13;
6. Buyuk AF, Kilinc E, Camurcu IY, Camur S, Ucpunar H, Kara A. Compared efficacy of intra-articular injection of methylprednisolone and triamcinolone. Acta Ortop Bras 2017;25:206-8. Sagar, et al.: Nano-formulation of Triamcinolone Acetonide&#13;
17 Pharmaspire | Vol. 14 | No. 1 | 2022 7. Bishnoi M, Jain A, Hurkat P, Jain SK. Aceclofenacloaded chondroitin sulfate conjugated SLNs for effective management of osteoarthritis. J Drug Target 2014;22:805-12.&#13;
8. Cevc G, Blume G, Schand;auml;tzlein AS. Transfersomesmediated transepidermal delivery improves the regiospecificity and biological activity of corticosteroids in vivo. J Control Release 1997;45:211-26.&#13;
9. Cevc G, Blume G. Biological activity and characteristics of triamcinolone-acetonide formulated with the selfregulating drug carriers, transfersomes. Biochim Biophy Acta 2003;2:156-64.&#13;
10. Hemalatha K, Prakatha RJ, Kavitha K, Sathiya S. A Cross-sectional Study on assessment of quality of life among patients with osteoarthritis. Int J Prevent Public Health Sci 2017;3:16-9.&#13;
11. Patel R, Singh SK, Singh S, Sheth NR, Gendle R. Development and characterization of curcumin loaded transfersome for transdermal delivery. J Pharm Sci Res 2009;1:71.&#13;
12. Ali SS, Gudipati M, Nadendla R. Development and characterization of miconazole nitrate transfersomal gel. Int J Res Pharm Sci Technol 2020;1:109-16.&#13;
13. Dudhipala N, Mohammed RP, Ali Youssef AA, Banala N. Effect of lipid and edge activator concentration on development of aceclofenac-loaded transfersomes gel for transdermal application: In vitro and ex vivo skin permeation. Drug Dev Ind Pharma 2020;46:1334-44.&#13;
14. Chen K, Li S, Yuan F, Sun P, Zhang Y. GEL-Man hydrogel loaded with triamcinolone acetonide for the treatment of osteoarthritis. Front Bioeng Biotechnol 2020;8:872.&#13;
15. Thakur N, Jain P, Jain V. Formulation development and evaluation of transferosomal gel. J Drug Deliv Ther 2018;8:168-77.&#13;
16. Ghanbarzadeh S, Arami S. Formulation and evaluation of piroxicam transferosomal gel: An approach for penetration enhancement. J Drug Deliv Sci Technol 2013;23:587-90.&#13;
17. Iannitti T, McDermott MF, Laurino C, Malagoli A, Palmieri B. Corticosteroid transdermal delivery significantly improves arthritis pain and functional disability. Drug Deliv Transl Res 2017;7:156-61.&#13;
18. Ajay G, Vinit MK. Formulation and evaluation of ketoprofen loaded protransfersome by using sodium deoxycholate and brij 35. Int J Curr Rev Res 2003;4:80-7.&#13;
19. Jain S, Jain P, Umamaheshwari RB, Jain NK. Transfersomes-a novel vesicular carrier for enhanced transdermal delivery: Development, characterization, and performance evaluation. Drug Dev Ind Pharm 2003;29:1013-26.&#13;
20. Kedor-Hackmann ER, Gianotto EA, Santoro MR. Determination of triamcinolone acetonide in ointment by UV derivative spectrophotometry and high performance liquid chromatography. Anal Lett 1997;30:1861-71.&#13;
21. Kloppenburg M, Berenbaum F. Osteoarthritis year in review 2019: Epidemiology and therapy. Osteoarthr Cartil 2020;28:242-8.&#13;
22. Lei W, Yu C, Lin H, Zhou X. Development of tacrolimusloaded transfersomes for deeper skin penetration enhancement and therapeutic effect improvement in vivo? Asian J Pharm Sci 2013;8:336-45.&#13;
23. Opatha SA, Titapiwatanakun V, Chutoprapat R. Transfersomes: A promising nanoencapsulation technique for transdermal drug delivery. Pharmaceutics 2020;12:855.&#13;
24. Piumitali B, Neeraj U, Jyotivardhan J. Transfersomes-A nanoscience in transdermal drug delivery and its clinical advancements. Int J Nanosci 2020;19:1950033.&#13;
25. Vandit S, Burzynski J, Zalzal P. Safety and efficacy of topical ketoprofen in transfersome gel in knee osteoarthritis: A systematic review. Musculoskeletal Care&#13;
2017;15:114-21. 26. Kumar A. Transferosome: A recent approach for transdermal drug delivery. J Drug Deliv Ther 2018;8:100-4.&#13;
27. Shuwaili AH, Rasool BK, Abdulrasool AA. Optimization of elastic transfersomes formulations for transdermal delivery of pentoxifylline. Eur J Pharma Biopharm 2016;102:101-14.</References>